Hussman Strategic Advisors Inc. Makes New Investment in Pacira BioSciences, Inc. $PCRX

Hussman Strategic Advisors Inc. purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 105,000 shares of the company’s stock, valued at approximately $2,706,000. Hussman Strategic Advisors Inc. owned 0.23% of Pacira BioSciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of PCRX. Y Intercept Hong Kong Ltd raised its position in Pacira BioSciences by 85.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 22,302 shares of the company’s stock valued at $575,000 after buying an additional 10,306 shares during the last quarter. Foster & Motley Inc. bought a new position in shares of Pacira BioSciences during the 3rd quarter worth approximately $388,000. SG Americas Securities LLC grew its stake in shares of Pacira BioSciences by 143.4% during the 3rd quarter. SG Americas Securities LLC now owns 15,702 shares of the company’s stock worth $405,000 after acquiring an additional 9,251 shares in the last quarter. KLP Kapitalforvaltning AS raised its holdings in shares of Pacira BioSciences by 36.1% in the third quarter. KLP Kapitalforvaltning AS now owns 47,900 shares of the company’s stock valued at $1,234,000 after purchasing an additional 12,700 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Pacira BioSciences by 76.2% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 54,800 shares of the company’s stock worth $1,412,000 after purchasing an additional 23,700 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PCRX has been the subject of a number of analyst reports. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Barclays started coverage on Pacira BioSciences in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Truist Financial reduced their price target on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $30.75.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $19.85 on Wednesday. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average price is $23.95 and its two-hundred day moving average price is $24.00. The company has a market cap of $853.95 million, a PE ratio of 44.11 and a beta of 0.22. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. The company had revenue of $179.52 million during the quarter, compared to analysts’ expectations of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The business’s revenue was up 6.5% on a year-over-year basis. During the same period last year, the firm posted $0.79 earnings per share. On average, analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Insider Buying and Selling at Pacira BioSciences

In other news, CFO Shawn Cross sold 15,896 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $25.03, for a total value of $397,876.88. Following the transaction, the chief financial officer directly owned 56,250 shares of the company’s stock, valued at $1,407,937.50. This represents a 22.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lauren Riker sold 1,416 shares of Pacira BioSciences stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $24.24, for a total transaction of $34,323.84. Following the sale, the senior vice president directly owned 59,064 shares of the company’s stock, valued at $1,431,711.36. The trade was a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 34,336 shares of company stock worth $851,868 over the last ninety days. Insiders own 6.40% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.